

Bioanalytical Sample Pre-treatment Procedures

Shahana Huq, Phenomenex, Torrance, CA, USA

Due to their nature, bioanalytical samples often require a pre-treatment step prior to further cleanup by solid phase extraction (SPE). Each sample matrix poses its own unique challenges such as the removal of proteins from plasma and serum, the disruption of red blood cells in whole blood, hydrolysis of glucuronidated analytes in urine, and homogenization of tissue samples. This technical note outlines common sample pre-treatment procedures for bioanalytical samples.

Plasma/Serum

Plasma and serum pre-treatments are analyte dependent. If the analyte of interest is an acid, 2% phosphoric acid can be used (20 μ L 85% H_3PO_4 to 1 mL of plasma or serum) to disrupt the drug-protein interaction. If the analyte of interest is basic, 0.1 M sodium hydroxide can be used to disrupt the drug-protein interaction. After addition of acid or base, the sample should be vortexed for 20-30 seconds followed by centrifugation. The supernatant is now ready for further analysis.

Whole Blood

There are several pre-treatment strategies that can be followed for whole blood. If the target analyte is present in red blood cells, a hemolysis step is necessary.

- Hemolysis:** To 0.2 mL whole blood (spiked with analytes and internal standard) in a 1.2 mL centrifuge tube, add 400 μ L of 2% zinc sulfate/80% methanol. Vortex for 10-20 seconds followed by centrifugation at 14,000 rpm for 10 minutes. Collect the supernatant for further analysis.

Preparation of zinc sulfate/methanol: Into a 100 mL volumetric flask add 20 mL water and 3.6 g $ZnSO_4 \cdot 7H_2O$. After the solution is clear and the salt crystals have dissolved, add 100% methanol. Refrigerate the solution at 2-8 $^{\circ}C$ for 7 days.

- Osmotic breakdown:** To 1 mL of whole blood add internal standard and 4 mL of distilled water. Mix/vortex and let stand for 5 minutes. Centrifuge at 670 g for 10 minutes and discard the pellet. Adjust the pH of the supernatant accordingly with the addition of a buffer solution.
- Sonication:** Sonicate 1 mL whole blood for 15 minutes at room temperature. Add 3-6 mL of an appropriate pH buffer (such as potassium phosphate buffer). Mix/vortex. Let stand for 5 minutes. Centrifuge at 670 g for 15 minutes. Analyze supernatant.

Note: A comparison of the above pre-treatment techniques for whole blood was performed for acidic, basic, and neutral drugs. Recoveries were generally the highest when the whole blood sample was diluted with buffer and subjected to physical denaturing (sonication) rather than chemical means. In fact, the sonication process disrupts the cell membranes to the extent that no clogging was observed when the procedure listed above was followed.¹

Urine

Enzymatic hydrolysis is necessary in case of conjugated forms (sulfated or glucuronide form) of the analyte present. Enzymatic hydrolysis requires specific pH (pH 4-5) and temperature ranges. An acid or base hydrolysis can be performed as well, depending on the stability of the compound.

- Enzymatic hydrolysis:** To 500 μ L sample (spiked with analyte and internal standard) add 100 μ L acidic buffer (see below) and 20 μ L beta-glucuronidase. Vortex 5-6 seconds. Incubate in a water bath at 63 $^{\circ}C$ for 30 minutes. Transfer sample to a 96-well collection plate or autosampler vial. Seal and centrifuge for 10 minutes at 2,000 rpm.

Preparation of acidic buffer (1.0 M acetate buffer, pH 4.0):

Dissolve 3.0 g of glacial acetic acid and 4.1 g of sodium acetate in a 1 L volumetric flask.

- Base hydrolysis:** To 1 mL urine (spiked with analyte and internal standard) add 100 μ L 10 N KOH. Mix, vortex, and hydrolyze for 20 minutes at 60 $^{\circ}C$. Cool and adjust pH to 3.5-4.0 (by adding 200 μ L glacial acetic acid).
- Acid hydrolysis:** To 1 mL urine add 0.25 mL HCl in a screw capped test tube. Screw the tube top on loosely and heat in a boiling water bath for 60 minutes. Adjust to pH 7 (or as needed) with 1.0 N NaOH.

Saliva

No hydrolysis is required for oral fluids and the generic protocol used for plasma/serum pre-treatment may be followed.

Tissue

Homogenize with organic or aqueous solvent depending upon analyte solubility. Settle, decant, centrifuge or filter supernatant. Perform direct Matrix Solid Phase Dispersion (MSPD) extraction on tissue.

References:

- Chen et al., *J. Anal. Toxicol.* 1992, v18, pages 352-355.



Australia

t: 02-9428-6444
 f: 02-9428-6445
 auinfo@phenomenex.com

Austria

t: 01-319-1301
 f: 01-319-1300
 anfrage@phenomenex.com

Belgium

t: 02 503 4015 (French)
 t: 02 511 8666 (Dutch)
 f: +31 (0)30-2383749
 beinfo@phenomenex.com

Canada

t: (800) 543-3681
 f: (310) 328-7768
 info@phenomenex.com

Denmark

t: 4824 8048
 f: +45 4810 6265
 nordicinfo@phenomenex.com

Finland

t: 09 4789 0063
 f: +45 4810 6265
 nordicinfo@phenomenex.com

France

t: 01 30 09 21 10
 f: 01 30 09 21 11
 franceinfo@phenomenex.com

Germany

t: 06021-58830-0
 f: 06021-58830-11
 anfrage@phenomenex.com

India

t: 040-3012 2400
 f: 040-3012 2411
 indiainfo@phenomenex.com

Ireland

t: 01 247 5405
 f: +44 1625-501796
 eireinfo@phenomenex.com

Italy

t: 051 6327511
 f: 051 6327555
 italiainfo@phenomenex.com

Luxembourg

t: +31 (0)30-2418700
 f: +31 (0)30-2383749
 nlinfo@phenomenex.com

Mexico

t: 001-800-844-5226
 f: 001-310-328-7768
 tecnicomx@phenomenex.com

The Netherlands

t: 030-2418700
 f: 030-2383749
 nlinfo@phenomenex.com

New Zealand

t: 09-4780951
 f: 09-4780952
 nzinfo@phenomenex.com

Norway

t: 810 02 005
 f: +45 4810 6265
 nordicinfo@phenomenex.com

Puerto Rico

t: (800) 541-HPLC
 f: (310) 328-7768
 info@phenomenex.com

Sweden

t: 08 611 6950
 f: +45 4810 6265
 nordicinfo@phenomenex.com

United Kingdom

t: 01625-501367
 f: 01625-501796
 ukinfo@phenomenex.com

United States

t: (310) 212-0555
 f: (310) 328-7768
 info@phenomenex.com

**All other countries:
Corporate Office USA** 

t: (310) 212-0555
 f: (310) 328-7768
 info@phenomenex.com



www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country, contact Phenomenex USA, International Department at international@phenomenex.com

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at <http://www.phenomenex.com/TermsAndConditions>.

© 2013 Phenomenex, Inc. All rights reserved.